JZJ(SH:605266)2022-08-29 16:00Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[17]. - The company's operating revenue for the first half of the year reached ¥3,006,192,004.54, representing a year-on-year increase of 26.34% compared to ¥2,379,397,214.91 in the same period last year[25]. - The company has set a revenue target of RMB 1.1 billion for the full year 2022, which would represent a growth of 10% compared to 2021[17]. - The company reported a total revenue of approximately CNY 3,006.19 million, with a year-on-year increase of 26.34%[85]. - The company achieved a total revenue of approximately 2,055.36 million CNY from its retail pharmacy operations, with a net profit of approximately 21.95 million CNY[142]. User Engagement and Growth - The number of active users reached 1.2 million, showing a growth of 20% compared to the same period last year[17]. - Active membership exceeded 19 million, marking a 26% increase from the previous year, with member consumption accounting for over 70% of total sales[99]. - The company has recruited a total of 1.3 million chronic disease members since 2011, establishing independent chronic disease files for each member[51]. Profitability and Margins - The gross profit margin improved to 30%, up from 28% in the previous year, indicating better cost management[17]. - The comprehensive gross profit margin improved to 35.99%, an increase of 0.88 percentage points compared to the same period last year[28]. - The net profit attributable to shareholders of the listed company was ¥87,997,028.51, a decrease of 28.16% from ¥122,491,573.08 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was ¥91,602,819.99, down 21.37% from ¥116,497,913.81 year-on-year[25]. - The gross profit margin for the pharmaceutical retail segment was 34.49%, reflecting an increase of 0.59% compared to the previous year[85]. Expansion Plans - The company plans to open 50 new stores by the end of 2022, expanding its market presence significantly[17]. - The company opened 253 new stores in the first half of 2022, resulting in a net increase of 239 stores, bringing the total to 3,283 stores, a growth rate of 7.85% compared to the end of 2021[72]. - The company plans to expand its market presence in the Sichuan-Chongqing-Guangxi region, with a focus on replicating its successful model from Yunnan[71]. - The company aims to enhance its retail network by opening new stores in Southwest provinces, with Chongqing and Guangxi already achieving profitability[43]. Operational Efficiency - The company experienced a significant increase in operating expenses by 36.64%, which was higher than the revenue growth rate, impacting net profit margins[28]. - The company is focusing on cost control measures, including negotiating rent reductions and improving promotional activity efficiency[117]. - The company is committed to continuous investment in refined operational management, efficient logistics, and optimized information systems[46]. Digital Transformation and E-commerce - The management emphasized the importance of digital transformation and plans to enhance its e-commerce capabilities[17]. - Online business revenue grew by 76.20% year-on-year, reaching ¥62,551,610, which now constitutes 20.81% of total operating income[99]. - The company is investing in a multi-channel service platform, integrating online and offline services to meet customer demands for health and convenience[42]. Acquisitions and Investments - The company plans to acquire 100% equity of Tangren Pharmaceutical in two phases, with the first phase involving the purchase of 80% equity already approved by the shareholders[34]. - The company acquired 100% equity of Chongqing Baorui Pharmacy for ¥71.48 million, involving 51 stores, completed on April 28, 2022[136]. - The company invested ¥10 million to acquire a 20% stake in Kunming Kangtesen Eye Hospital, further expanding its investment portfolio[137]. Risk Management - No significant risks were identified that could materially affect the company's operations during the reporting period[7]. - The company is focusing on risk control and enhancing operational quality to navigate the uncertainties in the market due to the pandemic[66]. - The company is addressing risks related to increasing customer demand and intensified market competition by improving service capabilities and operational efficiency[150]. Corporate Governance and Shareholder Relations - The company held three shareholder meetings during the reporting period, with no rejected resolutions or changes to previous decisions[164]. - The company did not distribute profits or increase capital reserves, with no dividends or stock bonuses declared[168]. - The company approved a stock incentive plan, allowing for the release of 267,601 shares for 148 incentive recipients, with a repurchase price set at 30.44 CNY per share[169][172].